Advances in and Insights into the Treatment of Glaucoma

Dear Colleagues,

Glaucoma is a chronic neurodegenerative disorder affecting the visual system which can result in vision loss and blindness. Glaucomatous optic neuropathy (GON) is the major cause of irreversible visual loss worldwide and can result from a range of disease etiologies. The defining features of GON are retinal ganglion cell (RGC) degeneration and characteristic cupping of the optic nerve head (ONH) due to tissue remodeling, while intraocular pressure remains the only modifiable GON risk factor currently targeted by approved clinical treatment strategies.

This Special Issue will summarize the different mechanisms of action, efficacy and side effects of current and recently launched intraocular pressure (IOP)-lowering medications. Conventionally, prostaglandin analogues are recommended as the first-choice treatment for POAG because of their efficacy and limited systemic side effects. Yet, the combination of agents of different classes with different mechanisms of action is associated with superior IOP-lowering efficacy compared to each of the components used alone. More information on new IOP-lowering medications including the nitric-oxide-donating prostaglandin analogue latanoprostene bunod, rho-kinase inhibitor netarsudil and fixed combination netarsudil/latanoprost will also be discussed. In addition, analysis on the pathogenesis of glaucoma with the combination of mechanisms and treatment strategies will also be covered.

This Special Issue, entitled "Advances in and Insights into the Treatment of Glaucoma", aims to collect original articles and review articles related to treatment and future perspectives in the management of glaucoma, which will help to advance knowledge in this field of research. This study will help ophthalmologists to design and develop new therapeutic strategies that can better control glaucoma progression.

Dr. Da-Wen Lu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• glaucoma
• glaucoma treatment
• molecular mechanism